Medarex, Inc. Prostate Cancer Drug Shows Promise
Reuters -- Shares of Medarex Inc rose as much as 22 percent Monday on a Mayo Clinic report that two prostate cancer patients became cancer-free after being treated with the company's experimental drug, ipilimumab, in combination with other therapies and surgery.